Cargando…
Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125998/ http://dx.doi.org/10.1186/1710-1492-10-S1-A42 |
| _version_ | 1782329847636295680 |
|---|---|
| author | Gerth, William C Betschel, Stephen D Zbrozek, Arthur S |
| author_facet | Gerth, William C Betschel, Stephen D Zbrozek, Arthur S |
| author_sort | Gerth, William C |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4125998 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-41259982014-08-12 Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada Gerth, William C Betschel, Stephen D Zbrozek, Arthur S Allergy Asthma Clin Immunol Meeting Abstract BioMed Central 2014-03-03 /pmc/articles/PMC4125998/ http://dx.doi.org/10.1186/1710-1492-10-S1-A42 Text en Copyright © 2014 Gerth et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Meeting Abstract Gerth, William C Betschel, Stephen D Zbrozek, Arthur S Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada |
| title | Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada |
| title_full | Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada |
| title_fullStr | Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada |
| title_full_unstemmed | Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada |
| title_short | Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada |
| title_sort | implications to payers of switch from hospital-based intravenous immunoglobulin (ivig) to home-based subcutaneous immunoglobulin (scig) therapy in patients with primary immunodeficiencies (pid) and secondary immunodeficiencies (sid) in canada |
| topic | Meeting Abstract |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125998/ http://dx.doi.org/10.1186/1710-1492-10-S1-A42 |
| work_keys_str_mv | AT gerthwilliamc implicationstopayersofswitchfromhospitalbasedintravenousimmunoglobulinivigtohomebasedsubcutaneousimmunoglobulinscigtherapyinpatientswithprimaryimmunodeficienciespidandsecondaryimmunodeficienciessidincanada AT betschelstephend implicationstopayersofswitchfromhospitalbasedintravenousimmunoglobulinivigtohomebasedsubcutaneousimmunoglobulinscigtherapyinpatientswithprimaryimmunodeficienciespidandsecondaryimmunodeficienciessidincanada AT zbrozekarthurs implicationstopayersofswitchfromhospitalbasedintravenousimmunoglobulinivigtohomebasedsubcutaneousimmunoglobulinscigtherapyinpatientswithprimaryimmunodeficienciespidandsecondaryimmunodeficienciessidincanada |